Ampio Pharmaceuticals, Inc. – AMEX:AMPE

Add to watchlist

$0.084

+0.08

+16600%

Market closed

Open in 2 days

-99.78%

month

-99.78%

quarter

-99.95%

year

Market Cap	2.95K
Enterprise value	N/A

P/E	-0.15
EV/Sales	N/A
EV/EBITDA	0.39
Price/Sales	N/A
Price/Book	0.27
PEG ratio	N/A
EPS	-10.7

Revenue	N/A
EBITDA	-9.33M
Income	-8.32M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Ampio Pharmaceuticals, Inc. (AMEX:AMPE): Profit margin
Mar 2023	0	-3.67M
Jun 2023	0	-1.37M
Sep 2023	0	-1.22M
Dec 2023	0	-2.05M

Ampio Pharmaceuticals, Inc. (AMEX:AMPE): Debt to assets
Mar 2023	10735000	2.85M	26.61%
Jun 2023	9149000	2.58M	28.3%
Sep 2023	7646000	2.27M	29.7%
Dec 2023	5736000	2.37M	41.42%

Ampio Pharmaceuticals, Inc. (AMEX:AMPE): Cash Flow
Mar 2023	-2.30M	0	0
Jun 2023	-3.39M	0	0
Sep 2023	-555K	0	0
Dec 2023	-2.30M	0	0

Ampio Pharmaceuticals alternative data

Ampio Pharmaceuticals
Employees

Ampio Pharmaceuticals, Inc. (AMEX:AMPE): Employee count
Aug 2023	8
Sep 2023	8
Oct 2023	8
Nov 2023	8
Dec 2023	5
Jan 2024	5
Feb 2024	5
Mar 2024	5
Apr 2024	5
May 2024	5
Jun 2024	6
Jul 2024	6

Ampio Pharmaceuticals
Hedge Funds Holdings Q3 2022

11.92% -1.55%

of AMPE is owned by hedge funds

68 -33

hedge funds hold AMPE stock

26.95M -3.50M

shares is hold by hedge funds

AMPE hedge funds holdings changes

Ampio Pharmaceuticals
Insider Trading

Ampio Pharmaceuticals, Inc. (AMEX:AMPE): Insider trades (number of shares)
Period	Buy	Sel
May 2023	271890	0
Jun 2023	46858	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	9 Jun 2023	BUCHI J KEVIN director director	Common Stock	21,858	$0.29	$6,295
Purchase	8 Jun 2023	BUCHI J KEVIN director director	Common Stock	25,000	$0.3	$7,400
Purchase	24 May 2023	MARTINO MICHAEL A director, officer: CEO director, officer: CEO	Common Stock	76,890	$0.29	$22,144
Purchase	16 May 2023	BUCHI J KEVIN director director	Common Stock	32,534	$0.27	$8,914
Purchase	15 May 2023	BUCHI J KEVIN director director	Common Stock	44,026	$0.25	$10,874
Purchase	12 May 2023	STEVENS DAVID R director director	Common Stock	45,000	$0.22	$9,900
Purchase	12 May 2023	BUCHI J KEVIN director director	Common Stock	23,440	$0.24	$5,508
Purchase	11 May 2023	STEVENS DAVID R director director	Common Stock	25,000	$0.22	$5,500
Purchase	11 May 2023	STEVENS DAVID R director director	Common Stock	25,000	$0.22	$5,375
Option	25 Jun 2021	STOKELY DAN officer: CFO officer: CFO	Common Stock	22,500	N/A	N/A

AMPE insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS FOR TREATING DISEASES ASSOCIATED WITH RESPIRATORY VIRUSES Filling date: 21 Mar 2022 Issue date: 7 Jul 2022	21 Mar 2022	7 Jul 2022
Grant	Grant Utility: Treatment of T-cell mediated diseases Filling date: 1 Oct 2020 Issue date: 28 Jun 2022	1 Oct 2020	28 Jun 2022
Grant	Grant Utility: Methods for treating diseases associated with respiratory viruses Filling date: 22 Sep 2021 Issue date: 22 Mar 2022	22 Sep 2021	22 Mar 2022
Application	Application COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME Filling date: 3 May 2021 Issue date: 20 Jan 2022	3 May 2021	20 Jan 2022
Application	Application METHODS FOR TREATING DISEASES ASSOCIATED WITH RESPIRATORY VIRUSES Filling date: 22 Sep 2021 Issue date: 13 Jan 2022	22 Sep 2021	13 Jan 2022
Application	Application IMPLANTABLE MEDICAL DEVICES WITH INCREASED IMMUNE TOLERANCE, AND METHODS FOR MAKING AND IMPLANTING Filling date: 28 Jun 2021 Issue date: 23 Dec 2021	28 Jun 2021	23 Dec 2021
Application	Application TREATMENT OF JOINT CONDITIONS Filling date: 8 Jul 2021 Issue date: 28 Oct 2021	8 Jul 2021	28 Oct 2021
Application	Application METHODS FOR TREATING DISEASES ASSOCIATED WITH RESPIRATORY VIRUSES Filling date: 24 Mar 2021 Issue date: 7 Oct 2021	24 Mar 2021	7 Oct 2021
Grant	Grant Utility: Methods for treating diseases associated with respiratory viruses Filling date: 24 Mar 2021 Issue date: 28 Sep 2021	24 Mar 2021	28 Sep 2021
Grant	Grant Utility: Treatment of joint conditions Filling date: 20 May 2019 Issue date: 17 Aug 2021	20 May 2019	17 Aug 2021

Ampio Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q4 2021 29 Mar 2022	Q4 2021 Earnings Call Transcript
Q3 2021 10 Nov 2021	Q3 2021 Earnings Call Transcript
Q2 2021 4 Aug 2021	Q2 2021 Earnings Call Transcript
Q1 2021 7 May 2021	Q1 2021 Earnings Call Transcript

AMPE earnings call transcripts

Ampio Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Michael E. Macaluso (1952) Founder, Chairman & Chief Executive Officer (Leave of Absence )	73	$457,040
Mr. Daniel G. Stokely CPA, CPA (1964) Chief Financial Officer, Corporation Sec. & Treasurer	61	$419,500
Ms. Holli Cherevka (1983) Pres & Chief Operating Officer	42	$288,040

Ampio Pharmaceuticals
Latest News

Wednesday, 3 April 2024
14:33	Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation	prnewswire.com
Monday, 25 March 2024
17:00	Ampio Announces Voluntary Delisting and SEC Deregistration	prnewswire.com
Wednesday, 14 February 2024
17:45	Ampio Provides Update on Results from Pre-IND Enabling Studies	prnewswire.com
Thursday, 11 January 2024
16:15	Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions	prnewswire.com
Tuesday, 31 October 2023
09:00	Ampio Pharmaceuticals to Present at the Emerging Growth Conference	prnewswire.com
Tuesday, 26 September 2023
09:15	Ampio Pharmaceuticals to Present at the Emerging Growth Conference	PRNewsWire
Thursday, 22 June 2023
09:30	3 Biotech Stocks to Buy With Explosive Upside Potential	InvestorPlace
Sunday, 4 September 2022
11:30	Which Strategies Are You Using With Penny Stocks in September?	PennyStocks
Friday, 22 April 2022
16:20	Why These 3 Penny Stocks Are Climbing in Late April	PennyStocks
Thursday, 21 April 2022
06:29	Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial	Benzinga
Thursday, 7 April 2022
08:17	New Strong Sell Stocks for April 7th	Zacks Investment Research
Friday, 1 April 2022
08:17	New Strong Sell Stocks for April 1st	Zacks Investment Research
Tuesday, 29 March 2022
18:41	Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 24 March 2022
09:41	Why Ampio Pharmaceuticals Stock Is Rising Today	Benzinga
Tuesday, 14 December 2021
13:49	Ampio (AMPE) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Thursday, 18 November 2021
11:28	Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Ampio (AMPE)	Zacks Investment Research
Wednesday, 10 November 2021
22:17	Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 13 October 2021
09:15	Ampio Pharmaceuticals Strengthens Management Team and Board of Directors	PRNewsWire
Tuesday, 21 September 2021
09:15	Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India	PRNewsWire
Thursday, 16 September 2021
15:07	Best Penny Stocks For Retail Traders to Buy? 3 For Your List	PennyStocks
Wednesday, 15 September 2021
11:04	Penny Stocks For Your Biotech Watch List In September 2021	PennyStocks
09:15	Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)	PRNewsWire
Friday, 13 August 2021
09:15	Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action	PRNewsWire

Ideas & Opinions

Seeking Alpha 13 Nov 2021

Merck's Plan B Percolates After Pfizer Announces Dominance
Seeking Alpha 23 May 2021

Ampio Pharmaceuticals: Regulatory Process Taking Too Long

Frequently Asked Questions (FAQ)

What's the price of Ampio Pharmaceuticals stock today?

One share of Ampio Pharmaceuticals stock can currently be purchased for approximately $0.08.
When is Ampio Pharmaceuticals's next earnings date?

Unfortunately, Ampio Pharmaceuticals's (AMPE) next earnings date is currently unknown.
Does Ampio Pharmaceuticals pay dividends?

No, Ampio Pharmaceuticals does not pay dividends.
How much money does Ampio Pharmaceuticals make?

Ampio Pharmaceuticals has a market capitalization of 2.95K.
What is Ampio Pharmaceuticals's stock symbol?

Ampio Pharmaceuticals, Inc. is traded on the AMEX under the ticker symbol "AMPE".
What is Ampio Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Ampio Pharmaceuticals?

Shares of Ampio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Ampio Pharmaceuticals's key executives?
Ampio Pharmaceuticals's management team includes the following people:
- Mr. Michael E. Macaluso Founder, Chairman & Chief Executive Officer (Leave of Absence )(age: 73, pay: $457,040)
- Mr. Daniel G. Stokely CPA, CPA Chief Financial Officer, Corporation Sec. & Treasurer(age: 61, pay: $419,500)
- Ms. Holli Cherevka Pres & Chief Operating Officer(age: 42, pay: $288,040)
Is Ampio Pharmaceuticals founder-led company?

Yes, Ampio Pharmaceuticals is a company led by its founder Mr. Michael E. Macaluso.
How many employees does Ampio Pharmaceuticals have?

As Jul 2024, Ampio Pharmaceuticals employs 6 workers, which is 20% more then previous quarter.
When Ampio Pharmaceuticals went public?

Ampio Pharmaceuticals, Inc. is publicly traded company for more then 15 years since IPO on 31 Mar 2010.
What is Ampio Pharmaceuticals's official website?

The official website for Ampio Pharmaceuticals is ampiopharma.com.
Where are Ampio Pharmaceuticals's headquarters?

Ampio Pharmaceuticals is headquartered at 373 Inverness Parkway, Englewood, CO.
How can i contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals's mailing address is 373 Inverness Parkway, Englewood, CO and company can be reached via phone at +7 204376500.

Ampio Pharmaceuticals, Inc.

ampiopharma.com

Exchange:

AMEX

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

+7 204376500

373 Inverness Parkway
Englewood, CO 80112

CIK: 0001411906
ISIN: US03209T3077
CUSIP: 03209T109